Konica Minolta Healthcare is partnering with RegenLab USA to distribute RegenLab’s portfolio of bio-injectable products to musculoskeletal, pain management, radiology, and veterinary markets in the United States and Canada.
Konica Minolta and RegenLab Ink Distribution Partnership
2 min read Premium comments
Secondary#ultrasoundimaging#bioinjectableproducts#konicaminoltaregenlab#ugpro
With RegenLab’s portfolio of injectable products, Konica Minolta Healthcare hopes to enhance its UGPro® program which combines ultrasound imaging with targeted therapies and hands-on education to improve patient outcomes. RegenLab’s bio-injectable product line includes platelet rich plasma (PRP) and other blood cell therapy devices which, because of the new partnership, can be delivered by physicians using Konica Minolta Healthcare’s SONIMAGE HS1 compact ultrasound system.
It’s a chocolate and peanut butter moment
Kirsten Doerfert, senior vice president of marketing at Konica Minolta Healthcare, provided some details behind the deal to OTW, “Konica Minolta’s focus is to bring complete solutions to our customers that provide more precise and personalized diagnosis and treatment for their patients. Our new partnership with RegenLab® USA supports that goal through the delivery of the highest quality, clinically validated orthobiologics.”
Doerfert continued, “RegenLab’s breadth of clinical evidence for its PRP system aligns with our strategy to advance innovation and education in MSK [musculoskeletal radiology] and orthopedic medicine. Our UGPro® Solution brings it all together by uniting Konica Minolta’s exceptional ultrasound imaging with targeted therapies and hands-on education to enhance patient care and help physicians grow their practice.”
According to Grand View Research, the regenerative medicine market for sports medicine, orthopedics, and pain management is experiencing rapid growth and projected to exceed $300 million in North America by 2025. “This growing demand for PRP and other cell therapies aligns with our UGPro strategy of bringing the highest quality, clinically validated solutions to our customers,” says Doerfert. “Our alliance with RegenLab is founded on our mutual belief in the importance of clinical evidence and the desire to help our customers better serve their patients.”
PRP is a concentration of platelets in plasma from a patient’s own blood. RegenLab’s kits allow physicians to easily, rapidly and consistently prepare a platelet concentration from a small volume of blood. Since, ideally, these procedures are performed under ultrasound guidance (with ultrasound guidance, the accuracy of nearly every joint injection exceeds 90%) the deal with Konica appears to be a natural.
“As a leading innovator for the preparation of PRP, safety and efficacy of our products is paramount,” says Antoine Turzi, RegenLab founder and chief executive officer. “Our alliance with Konica Minolta Healthcare further advances this area of medicine by giving physicians the ability to guide the accurate delivery of cell therapy prepared with Regen Lab products.”
Since 2003, RegenLab has provided high-quality medical devices for over one million treatments using cellular therapies and PRP.
Konica Minolta Healthcare, headquartered in Wayne, New Jersey, provides medical diagnostic imaging and healthcare information technology. Konica Minolta Healthcare is a unit of Konica Minolta, Inc.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.